Velocity Clinical Research, Inc.

On this day of Thanksgiving, we pause to reflect on the blessings that surround us — family, friends, health, and the joys of life. At Velocity, we are thankful for the opportunity to contribute to advancements in science and improve lives. We're also grateful for our patients, clients, and partners for your trust and support. May your day be filled with warmth, laughter, and love. Happy Thanksgiving!

Latin America is becoming one of the most important regions in the world for accelerating high-quality clinical research and Velocity is committed to being part of that growth in a meaningful, long-term way. That’s why we invested in the region by putting boots on the ground, starting with the hiring of Renata Berardocco, who brings deep regional expertise and a passion for strengthening partnerships with sponsors, CROs, investigators, and patient communities across LATAM. Renata represented Velocity this week at SCRS Latin America, where the energy, collaboration, and forward momentum across the region were unmistakable. As more trials expand into LATAM, and as patient access, diversity, and speed become global priorities, strong, integrated site networks have a critical role to play. Latin America is a strategic cornerstone for the future of global clinical development. We couldn’t be more excited to grow our presence and invest in the teams driving research forward. #ClinicalResearch #LATAM #SCRS #VelocityClinicalResearch #GlobalTrials #SiteNetworks #ClinicalOperations #DiversityInResearch

This edition of The Recap is introduced by Andrew Reina, Chief Revenue Officer. He shares his thoughts on joining the team, and why Velocity is uniquely positioned to change the way Sponsors and CROs partner with sites. Tap or click below to read The Recap 🔄️

Frederick "Fritz" Raiser MD is an emergency medicine physician and principal investigator at Velocity Clinical Research in Omaha. His story is a reminder of how clinical research and emergency care are deeply connected — and how one physician can bridge two worlds that don't usually mix in most people's minds. When the COVID-19 pandemic hit, Dr. Raiser enrolled patients into Phase 3 vaccine trials. Just months later, he saw those same vaccines administered in the ER. Today, vaccine research remains a cornerstone of the Omaha site, from RSV and norovirus to emerging infectious threats. But obesity care is where Dr. Raiser sees some of the most transformative patient outcomes. He’s now preparing for Board Certification in Obesity Medicine as Velocity continues to expand its work in this critical area. Read his unique story: https://lnkd.in/exUC4S44

For too long, clinical research has relied on a tactical model of site engagement, assembling networks for a single study, stretching them to their limits, and dissolving them the moment the last patient completes their final visit. In his latest op-ed for Clinical Leader, AMRC Executive Director Jim Kremidas argues that this model is no longer sustainable. Fragmentation, inconsistent oversight, and short-term thinking create avoidable barriers to speed, predictability, and quality. What’s needed now is a shift from tactical engagement to strategic partnership — the same evolution CROs went through two decades ago. 👉 Read Jim's latest article here: https://lnkd.in/ddmJVkft #ClinicalTrials #ClinicalResearch #MCRC #LifeSciences #Sites #CRO #Sponsors #Innovation #ClinicalOperations #ResearchLeadership

At ObesityWeek® in Atlanta, Stanley Hsia, MD, presented results from a Phase 2 Eli Lilly and Company/Innovent Biologics study on mazdutide, a once-weekly injectable GLP-1/glucagon dual agonist. The study demonstrated dose-dependent weight loss. Dr. Hsia: "All of these mazdutide treatment curves did not seem to plateau, suggesting that had we continued treatment beyond 48 weeks, greater degrees of weight loss might actually have been seen." Participants experienced decreased HbA1c, and those on higher-dose regimens (10 and 16 mg) also experienced declines in LDL cholesterol, non-HDL cholesterol, and triglycerides. Read the full recap from Healio: https://lnkd.in/g_dW2zZc

Did you hear the news? Andrew Reina has joined Velocity as Chief Revenue Officer. Former Fortrea and PPD, Drew will oversee delivery for building startegic relationships with Sponsors and CROs, as Velocity continues to scale its operations and enroll participants among myriad therepeutic areas, including obesity, cardiometabolic, central nervous system diseases and vaccine research. But don't just trust us, read the news for yourself: - BioSpace: https://lnkd.in/egD6NzN6 - The Associated Press: https://lnkd.in/eHwfH5qr - Investors Hangout: https://lnkd.in/e7RAiZCr - Yahoo Finance: https://lnkd.in/eDhgeRBS

Last week, Velocity Clinical Research hosted a private dinner during ObesityWeek® in Atlanta, bringing together senior leaders from Sponsors and CROs for an off-the-record discussion with Jerome Adams, MD, MPH, the 20th U.S. Surgeon General. We welcomed executives from IQVIA, AltrixBio Inc., Fortrea, Boehringer Ingelheim and Roche. In an insightful keynote, Dr. Adams shared his perspective on the state of the clinical research industry, the growing importance of diversity in trials, and reflections from his time in the Trump Administration, shaping national health policy. The discussion that followed — held under Chatham House rules — was thoughtful, candid, and future-focused, underscoring the importance of open dialogue between site networks, Sponsors, and CROs as the landscape of clinical research continues to evolve. We’re grateful to all who joined us for the evening and contributed to a meaningful exchange of ideas about how we can work together to improve access, quality, and outcomes for patients. Looking forward to the next one!

Velocity Clinical Research welcomes Andrew Reina as Chief Revenue Officer (CRO). Drew brings more than two decades of global clinical research experience, having led high-performing commercial teams and strategic partnerships at both Fortrea (formerly Labcorp Drug Development) and PPD, where he oversaw a $1B+ global portfolio of Phase II–IV studies. “This has been a challenging year for clinical research in many ways,” said Paul Evans, President & CEO of Velocity. “Andrew’s experience at Fortrea brings deep CRO-centric leadership to our team and helps position Velocity not just as an exceptional site network, but as a strategic partner — particularly for biotech and leading pharma companies.” “Sponsors and CROs increasingly rely on MCRCs to accelerate speed to market and reduce burden on both sites and patients,” added Drew Reina. “Velocity is exceptionally positioned to meet those needs, and I’m energized by the opportunity to contribute to its continued growth and impact.” As Velocity enters a new phase of consolidation and growth, Drew’s appointment reinforces our mission to deliver high-quality, patient-focused research through a holistic operations and commercial strategy, helping Sponsors and CROs bring new treatments to patients faster, with greater consistency and quality. Learn more about Drew's appointment and Velocity’s integrated site network: https://lnkd.in/gchGT9ca

This Veteran's Day, we pay tribute to the brave men and women who have selflessly served. Your sacrifices and dedication inspire us all. Join us in saluting our heroes and standing together in appreciation and respect.